Search

Your search keyword '"Gawlowicz, Jacek"' showing total 4 results
Start Over Author "Gawlowicz, Jacek" Search Limiters Full Text

Refine your results

more »

more »
4 results on '"Gawlowicz, Jacek"'

1. Mechanical thrombectomy in acute stroke – Five years of experience in Poland

Author

Słowik, Agnieszka, Wnuk, Marcin, Brzegowy, Paweł, Chrzanowska-Waśko, Joanna, Golenia, Aleksandra, Łasocha, Bartłomiej, Włoch-Kopeć, Dorota, Ferens, Antoni, Serednicki, Wojciech, Jarocki, Piotr, Bartosik-Psujek, Halina, Kaczorowski, Rafał, Filip, Edward, Grzegorzak, Monika, Homa, Jarosław, Darocha, Janusz, Dudek, Daniel, Guz, Wiesław, Rejdak, Konrad, Luchowski, Piotr, Wojczal, Joanna, Sojka, Michał, Górnik, Michał, Stachowicz, Sylwia, Jaworski, Jacek, Buraczyńska, Kinga, Ficek, Remigiusz, Szczepańska-Szerej, Anna, Jargiełło, Tomasz, Szczerbo-Trojanowska, Małgorzata, Lasek-Bal, Anetta, Puz, Przemysław, Warsz-Wianecka, Aldona, Stęposz, Arkadiusz, Ziaja, Krzysztof, Kuczmik, Wacław, Urbanek, Tomasz, Ziaja, Damian, Tomalski, Witold, Kobayashi, Adam, Richter, Przemysław, Płoński, Andrzej, Kotkowski, Marcin, Czepiel, Wojciech, Kurkowska-Jastrzębska, Iwona, Sienkiewicz-Jarosz, Halina, Członkowska, Anna, BłażejewskaHyżorek, Beata, Ryglewicz, Danuta, Konopko, Magdalena, Brelak, Edyta, Antecki, Jacek, Szydłowski, Igor, Włosek, Maciej, Stępień, Adam, Brzozowski, Krzysztof, Staszewski, Jacek, Piasecki, Piotr, Zięcina, Piotr, Wołoszyńska, Izabela, Kolmaga, Norbert, Narloch, Jerzy, Hasiec, Tomasz, Gawłowicz, Jacek, Pędracka, Monika, Porębiak, Jacek, Grzechnik, Bogumił, Matsibora, Vadym, Frąszczak, Michał, Leus, Marcin, Mazgaj, Maciej, Palacz-Duda, Violetta, Meder, Grzegorz, Skura, Wojciech, Płeszka, Piotr, Świtońska, Milena, Słomiński, Krzysztof, Kościelniak, Józef, Sobieszak-Skura, Paulina, Konieczna-Brazis, Magdalena, Rowiński, Olgierd, Opuchlik, Andrzej, Mickielewicz, Anatol, Szyluk, Beata, Szczudlik, Piotr, Kostera-Pruszczyk, Anna, Jaworski, Maciej, Maciąg, Rafał, Żyłkowski, Jarosław, Adamkiewicz, Bożena, Szubert, Wojciech, Chrząstek, Jarosław, Raźniewski, Marek, Pawelec, Agnieszka, Wilimborek, Paweł, Wagner, Ryszard, Pilarski, Paweł, Gierach, Paweł, Baron, Jan, Gruszka, Wojciech, Ochudło, Stanisław, Krzak-Kubica, Agnieszka, Rudzińska-Bar, Monika, Zbroszczyk, Miłosz, Smulska, Kamila, Arkuszewski, Michał, Różański, Dorota, Koziorowski, Dariusz, Meisner-Kramarz, Izabela, Szlufik, Stanisław, Zaczyński, Artur, Kądziołka, Krzysztof, Kordecki, Kazimierz, Zawadzki, Michał, Ząbek, Mirosław, Karaszewski, Bartosz, Gąsecki, Dariusz, Łowiec, Paweł, Dorniak, Waldemar, Gorycki, Tomasz, Szurowska, Edyta, Wierzchowska-Cioch, Ewa, Smyk, Tomasz, Szajnoga, Beata, Bachta, Marcin, Mazurek, Kajetan, Piwowarska, Magdalena, Kociemba, Wojciech, Drużdż, Artur, Dąbrowski, Adrian, Glonek, Michał, Wawrzyniak, Małgorzata, Kaźmierski, Radosław, Juszkat, Robert, Heliosz, Adam, Ryszczyk, Adam, Zwiernik, Jacek, Wasilewski, Grzegorz, Tutaj, Andrzej, Dałek, Grzegorz, Nosek, Krzysztof, Bereza, Sławomir, Lubkowska, Katarzyna, Kamienowski, Jerzy, Sobolewski, Piotr, Bielecki, Adam, Miś, Maciej, Miś, Marcin, Krużewska-Orłowska, Maria, Kochanowicz, Jan, Mariak, Zenon, Jakoniuk, Marta, Turek, Grzegorz, Łebkowska, Urszula, Lewszuk, Andrzej, Dziedzic, Tomasz, and Popiela, Tadeusz

Published
2017
Full Text
View/download PDF

2. Prospective of ischemic stroke biomarkers

Author

Szewczak Krzysztof, Niespialowska Magdalena, Jakubowska-Solarska Beata, Chalabis Magdalena, and Gawlowicz Jacek

Subjects
ischemic stroke, biomarker, inflammation, cytokines, Medicine
Abstract

Methods currently used in brain vascular disorder diagnostics are neither fast enough nor clear-out; thus, there exists a necessity of finding new types of testing which could enlarge and complete the actual panel of diagnostics or be an alternative to current methods. The discovery of sensitive and specific biomarkers of ischemic brain stroke will improve the effects of treatment and will help to assess the progress or complications of the disease. The relevant diagnosis of ischemic stroke (IS) within the first 4.5 hours after the initial symptoms allows for the initiation of treatment with recombinant tissue plasminogen activators which limits the magnitude of negative changes in the brain and which enhance the final effectiveness of therapy. The potential biomarkers which are under investigation are substances involved in the processes of coagulation and fibrinolysis, and are of molecules released from damaged vascular endothelial cells and from nerves and cardiac tissue. The analyzed substances are typical of oxidative stress, apoptosis, excitotoxicity and damage of the blood brain barrier.

Published
2017
Full Text
View/download PDF

3. Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Drug-Resistant Epilepsy in the MORE Multicenter Patient Registry

Author

Peltola, Jukka, Colon, Albert A., Pimentel, Jose, Coenen, Volker, Gil-Nagel, Antonio, Goncalves Ferreira, Antonio, Lehtimaki, Kai S., Ryvlin, Philippe, Taylor, Rod, Ackermans, Linda, Ardesch, Jacqueline, Bentes, Carla G., Bosak, Magdalena, Burneo, Jorge E., Chamadoira, Clara, Elger, Christian, Eross, Lorand, Fabo, Daniel, Faulkner, Howard, Gawlowicz, Jacek, Gharabaghi, Alireza, Iacoangeli, Maurizio, Janszky, Jozsef, Jarvenpaa, Soila H., Kaufmann, Elisabeth, Kho, Kuan H., Kumlien, Eva, Laufs, Helmut, Lettieri, Christian, Linhares, Paulo, Noachtar, Soheyl, Parrent, Andrew K., Pataraia, Ekaterina, Patel, Nikunj K., Peralta, Ana Rita, Racz, Attila, Campos, Alexandre Rainha A., Rego, Ricardo, Ricciuti, Riccardo, Rona, Sabine, Rouhl, Rob P. W., Schulze-Bonhage, Andreas, Schuurman, Rick, Sprengers, Mathieu, Sufianov, Albert, Temel, Yasin, Theys, Tom, Van Paesschen, Wim, Van Roost, Dirk, Vaz, Rui, Vonck, Kristl, Wagner, Louis, Zwemmer, Jack C., Abouihia, Abdallah, Brionne, Thomas, Gielen, Frans, Boon, Paul A. J. M., Peltola, Jukka, Colon, Albert A., Pimentel, Jose, Coenen, Volker, Gil-Nagel, Antonio, Goncalves Ferreira, Antonio, Lehtimaki, Kai S., Ryvlin, Philippe, Taylor, Rod, Ackermans, Linda, Ardesch, Jacqueline, Bentes, Carla G., Bosak, Magdalena, Burneo, Jorge E., Chamadoira, Clara, Elger, Christian, Eross, Lorand, Fabo, Daniel, Faulkner, Howard, Gawlowicz, Jacek, Gharabaghi, Alireza, Iacoangeli, Maurizio, Janszky, Jozsef, Jarvenpaa, Soila H., Kaufmann, Elisabeth, Kho, Kuan H., Kumlien, Eva, Laufs, Helmut, Lettieri, Christian, Linhares, Paulo, Noachtar, Soheyl, Parrent, Andrew K., Pataraia, Ekaterina, Patel, Nikunj K., Peralta, Ana Rita, Racz, Attila, Campos, Alexandre Rainha A., Rego, Ricardo, Ricciuti, Riccardo, Rona, Sabine, Rouhl, Rob P. W., Schulze-Bonhage, Andreas, Schuurman, Rick, Sprengers, Mathieu, Sufianov, Albert, Temel, Yasin, Theys, Tom, Van Paesschen, Wim, Van Roost, Dirk, Vaz, Rui, Vonck, Kristl, Wagner, Louis, Zwemmer, Jack C., Abouihia, Abdallah, Brionne, Thomas, Gielen, Frans, and Boon, Paul A. J. M.

Abstract

Background and Objectives The efficacy of deep brain stimulation of the anterior nucleus of the thalamus (ANT DBS) in patients with drug-resistant epilepsy (DRE) was demonstrated in the double-blind Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy randomized controlled trial. The Medtronic Registry for Epilepsy (MORE) aims to understand the safety and longer-term effectiveness of ANT DBS therapy in routine clinical practice. Methods MORE is an observational registry collecting prospective and retrospective clinical data. Participants were at least 18 years old, with focal DRE recruited across 25 centers from 13 countries. They were followed for at least 2 years in terms of seizure frequency (SF), responder rate (RR), health-related quality of life (Quality of Life in Epilepsy Inventory 31), depression, and safety outcomes. Results Of the 191 patients recruited, 170 (mean [SD] age of 35.6 [10.7] years, 43% female) were implanted with DBS therapy and met all eligibility criteria. At baseline, 38% of patients reported cognitive impairment. The median monthly SF decreased by 33.1% from 15.8 at baseline to 8.8 at 2 years (p < 0.0001) with 32.3% RR. In the subgroup of 47 patients who completed 5 years of follow-up, the median monthly SF decreased by 55.1% from 16 at baseline to 7.9 at 5 years (p < 0.0001) with 53.2% RR. High-volume centers (>10 implantations) had 42.8% reduction in median monthly SF by 2 years in comparison with 25.8% in low-volume center. In patients with cognitive impairment, the reduction in median monthly SF was 26.0% by 2 years compared with 36.1% in patients without cognitive impairment. The most frequently reported adverse events were changes (e.g., increased frequency/severity) in seizure (16%), memory impairment (patient-reported complaint, 15%), depressive mood (patient-reported complaint, 13%), and epilepsy (12%). One definite sudden unexpected death in epilepsy case was reported. Discussion The MORE registry supports t

Published
2023
Full Text
View/download PDF

4. Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex

Author

Thiele, Elizabeth A., Bebin, E. Martina, Bhathal, Hari, Jansen, Floor E., Kotulska, Katarzyna, Lawson, John A., O'Callaghan, Finbar J., Wong, Michael, Sahebkar, Farhad, Checketts, Daniel, Knappertz, Volker, Archer, John, Arndt, Daniel H., Barron, Todd, Cantarín-Extremera, Verónica, Sanchez-Carpintero, Rocio, Ciliberto, Michael A., Cock, Hannah, De Wit, Marie-Claire Y., Devinsky, Orrin, Falip, Merce, Filloux, Francis M., Fountain, Nathan B., Gawlowicz, Jacek, Greenwood, Robert S., Hamandi, Khalid, Joshi, Charuta, Józwiak, Sergiusz, Klein, Pavel, Kwan, Patrick, Lisewski, Pawel, Miller, Ian O., Morse, Richard P., Mostajelean, Ali S., Nolan, Danielle A., O'Brien, Terence J., Paredes, Fernando, Perry, M. Scott, Ramos, Federico J., Reutens, David, Roberts, Colin M., Saneto, Russell P., Sharp, Gregory B., Saxena, Anurag, Sparagana, Steven P., Tatachar, Priyamvada, Wheless, James W., Wirrell, Elaine C., Wong, Matthew H., Wu, Joyce Y., and Zolnowska, Marta

Abstract

Importance Efficacy of cannabidiol has been demonstrated in seizures associated with Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in conditions with primarily focal seizures, such as tuberous sclerosis complex (TSC).Objective To evaluate efficacy and safety of 25-mg/kg/day and 50-mg/kg/day cannabidiol dosages vs placebo against seizures associated with TSC.Design, Setting, and Participants This double-blind, placebo-controlled randomized clinical trial (GWPCARE6) enrolled patients between April 6, 2016, and October 4, 2018; follow-up was completed on February 15, 2019. The trial was conducted at 46 sites in Australia, Poland, Spain, the Netherlands, United Kingdom, and United States. Eligible patients (aged 1-65 years) were those with a clinical diagnosis of TSC and medication-resistant epilepsy who had had at least 8 TSC-associated seizures during the 4-week baseline period, with at least 1 seizure occurring in at least 3 of the 4 weeks, and were currently taking at least 1 antiepileptic medication.Interventions Patients received oral cannabidiol at 25 mg/kg/day (CBD25) or 50 mg/kg/day (CBD50) or a matched placebo for 16 weeks.Main Outcomes and Measures The prespecified primary outcome was the change from baseline in number of TSC-associated seizures for cannabidiol vs placebo during the treatment period.Results Of 255 patients screened for eligibility, 31 were excluded and 224 were randomized. Of the 224 included patients (median [range] age, 11.4 [1.1-56.8] years; 93 female patients [41.5%]), 75 were randomized to CBD25, 73 to CBD50, and 76 to placebo, with 201 completing treatment. The percentage reduction from baseline in the type of seizures considered the primary end point was 48.6% (95% CI, 40.4%-55.8%) for the CBD25 group, 47.5% (95% CI, 39.0%-54.8%) for the CBD50 group, and 26.5% (95% CI, 14.9%-36.5%) for the placebo group; the percentage reduction from placebo was 30.1% (95% CI, 13.9%-43.3%; P

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results